MedTrace Logo

The Raltegravir and Ribavirin Pharmacokinetics (PK) Study

NCT00982553 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-10-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to look at levels of both a new anti-HIV drug called raltegravir and an existing anti-hepatitis C drug called ribavirin to see if they affect the blood levels of each other when given separately and together. This is a phase I, open-label, prospective, three phase, pharmacokinetic study.

Conditions

  • HIV Infections

Interventions

DRUG

Ribavirin

800mg once daily

DRUG

Raltegravir

400mg twice daily

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Alan Winston, MB BH · Imperial College London

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2009-11-30
Completion
2009-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00982553 on ClinicalTrials.gov